ARID2 Loss Reprograms the Kynurenine-AhR Pathway to Restore Antitumor Immunity in CTNNB1-Mutant Hepatocellular Carcinoma.

Loss of ARID2 reprograms the kynurenine-AhR pathway to restore antitumor immunity in CTNNB1-mutant hepatocellular carcinoma.

• Why it matters: Understanding metabolic mechanisms that cause immune exclusion in CTNNB1-mutant HCC is crucial for improving immunotherapy responses, as these tumors are typically resistant to immune checkpoint blockade.
• What they did: Researchers analyzed patient data and mouse models with co-mutations of CTNNB1 and ARID2, revealing that ARID2 loss reduces TDO2-driven kynurenine production, decreases MDSC infiltration, and enhances T cell activity, especially when combined with anti-PD-1 therapy.
• The result: Pharmacological inhibition of AhR mimicked ARID2 loss effects and, combined with anti-PD-1, reversed immune-cold phenotypes, suggesting targeting the TDO2-kynurenine-AhR pathway may improve immunotherapy efficacy in CTNNB1-mutant HCC.